319 related articles for article (PubMed ID: 36136330)
21. Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer.
Karam R; Conner B; LaDuca H; McGoldrick K; Krempely K; Richardson ME; Zimmermann H; Gutierrez S; Reineke P; Hoang L; Allen K; Yussuf A; Farber-Katz S; Rana HQ; Culver S; Lee J; Nashed S; Toppmeyer D; Collins D; Haynes G; Pesaran T; Dolinsky JS; Tippin Davis B; Elliott A; Chao E
JAMA Netw Open; 2019 Oct; 2(10):e1913900. PubMed ID: 31642931
[TBL] [Abstract][Full Text] [Related]
22. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
23. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK
Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596
[TBL] [Abstract][Full Text] [Related]
24. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
25. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
Bandeira G; Rocha K; Lazar M; Ezquina S; Yamamoto G; Varela M; Takahashi V; Aguena M; Gollop T; Zatz M; Passos-Bueno MR; Krepischi A; Okamoto OK
Breast Cancer; 2021 Mar; 28(2):346-354. PubMed ID: 32986223
[TBL] [Abstract][Full Text] [Related]
26. Influence of germline test results on surgical decision making in women with invasive breast cancer.
Vargason AB; Turner CE; Shriver CD; Ellsworth RE
Cancer Genet; 2022 Aug; 266-267():81-85. PubMed ID: 35868102
[TBL] [Abstract][Full Text] [Related]
27. Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?
Metcalfe KA; Narod SA; Eisen A; Poll A; Zamani N; McCready D; Cil TD; Wright FC; Lerner-Ellis J; McCuaig J; Graham T; Sun P; Akbari MR
Cancer Med; 2023 Mar; 12(6):7580-7587. PubMed ID: 36544278
[TBL] [Abstract][Full Text] [Related]
28. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing.
Chen E; Facio FM; Aradhya KW; Rojahn S; Hatchell KE; Aguilar S; Ouyang K; Saitta S; Hanson-Kwan AK; Capurro NN; Takamine E; Jamuar SS; McKnight D; Johnson B; Aradhya S
JAMA Netw Open; 2023 Oct; 6(10):e2339571. PubMed ID: 37878314
[TBL] [Abstract][Full Text] [Related]
29. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Piccinin C; Panchal S; Watkins N; Kim RH
Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018
[No Abstract] [Full Text] [Related]
30. Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
Koptiuch C; Espinel WF; Kohlmann WK; Zhao J; Kaphingst KA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250392
[TBL] [Abstract][Full Text] [Related]
31. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
[TBL] [Abstract][Full Text] [Related]
32. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
[TBL] [Abstract][Full Text] [Related]
33. Pivotal Role of Genetic Counselors in the Uptake of Germline Genetic Testing in Non-Metastatic Breast Cancer and the Impact of Testing on Surgical Decision Making.
Erali RA; Pu T; Vu TM; Mangieri CW; Jee Y; Wise JS; Perry KC; Hsu FC; Levine EA; McNatt MH; Chiba A
Am Surg; 2023 Dec; 89(12):5842-5849. PubMed ID: 37183417
[TBL] [Abstract][Full Text] [Related]
34. Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations.
Horton C; Blanco K; Lo MT; Speare V; LaDuca H; Dolinsky JS; Kurian AW
JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603838
[TBL] [Abstract][Full Text] [Related]
35. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.
Andoni T; Wiggins J; Robinson R; Charlton R; Sandberg M; Eeles R
Sci Rep; 2022 Feb; 12(1):2507. PubMed ID: 35190596
[TBL] [Abstract][Full Text] [Related]
36. Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
Greenberg SE; Hunt TC; Ambrose JP; Lowrance WT; Dechet CB; O'Neil BB; Tward JD
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250421
[TBL] [Abstract][Full Text] [Related]
37. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
38. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
[TBL] [Abstract][Full Text] [Related]
39. [Susceptibility study on the germline rare variants of bromodomain and extraterminal domain protein family-encoding genes and patients with cancer living in some regions of China].
Huang Y; Li JH; Wang X; Zou Y; Huang WF; Liu C; Zhang H
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(42):3374-3381. PubMed ID: 36372767
[No Abstract] [Full Text] [Related]
40. Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
Tsaousis GN; Papadopoulou E; Agiannitopoulos K; Pepe G; Tsoulos N; Boukovinas I; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Kapsimalis A; Xepapadakis G; Psyrri A; Banu E; Eniu DT; Blidaru A; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
Cancer Genomics Proteomics; 2022; 19(1):60-78. PubMed ID: 34949660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
